XtalPi
Data as of .
Company facts
-
Founded
2015
-
Headquarters
China (Shenzhen; HKEX listed)
Latest funding round
- Round
- Convertible bonds
- Date
- Jan 28, 2026
- Amount
- HKD 2.866B (approx. $367.4M)
Drug discovery partners
0 pharma, 3 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
META Pharmaceuticals Biotech
MP-5342 preclinical milestones,
Terms not disclosed
-
DoveTree Biotech
Discovery collaboration,
$51M upfront ($5.99B total potential)
-
Undisclosed global biopharma Type not disclosed
Collaboration and license,
$400M total potential (upfront not disclosed)
Drugs on the board
- XtalPi topical hair loss candidate
IND-enabling per company
Androgenetic alopecia
- KQTD-126 (pan-TRK inhibitor)
IND submitted (US), not yet in effect per company
Chronic intestinal pain (IBS and IBD)
- MP-5342 (LDHA inhibitor)
IND-enabling per company
Autoimmune disease
- XtalPi HIV entry candidate
Preclinical candidate per company
HIV
Recent news
-
Submitted US IND for KQTD-126, gut-restricted pan-TRK inhibitor
-
Preclinical candidate for HIV entry with incubated company Viva-Thera
-
Subsidiary LCC Technologies launched collaboration with Stanford
-
Preclinical milestones with META Pharmaceuticals for MP-5342 (LDHA inhibitor)
-
PepiX-designed p53 peptides showed antitumor activity in mice
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.